Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial Watch the “What This Means” segment here ISELIN, N.J., Feb. 04, 2025 ...

Compounded bevacizumab formulations are sometimes ... data suggests Lytenava is more effective than ranibizumab as a treatment for wet AMD, and offers similar efficacy to aflibercept and faricimab.

Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

2025 年欧洲肺癌大会（ELCC）将于当地时间 3 月 26 日至 29 日在法国巴黎以线上结合线下的形式举行。本次会议旨在传播胸部恶性肿瘤前沿研究进展，为全球相关领域研究人员和医务人员提供高水平的医学教育与良好的学术交流机会。 今年的 ELCC ...

Ozone therapy is a controversial alternative medicine practice that involves using ozone gas to fight disease. Currently, there is not enough evidence to conclude it is effective or safe for ...

ImmunoGen’s president and CEO, Mark Enyedy, said: “With an indication for use regardless of prior treatment with Avastin, we believe ELAHERE is positioned to become the new standard of care ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.